Loading...
•
Dec 31, 2021
Atricure Q4 2021 Earnings Report
AtriCure's Q4 2021 financial results were reported, showing revenue increase.
Key Takeaways
AtriCure reported a 26.8% increase in revenue for Q4 2021, reaching $73.2 million. The U.S. revenue grew by 29.1% to $61.2 million, driven by strong growth across all product lines. The company's loss from operations was $12.5 million, and the net loss per share was $0.30.
Q4 2021 revenue increased by 26.8% to $73.2 million.
U.S. revenue increased by 29.1% to $61.2 million, driven by cryoSPHERE®, EPi-Sense and AtriClip® Flex⋅V® products.
International revenue increased by 16.3% to $12.0 million.
Basic and diluted net loss per share was $0.30.
Forward Guidance
Full year 2022 revenue is projected to be approximately $315 million to $330 million, reflecting growth of approximately 15% to 20% over full year 2021. Full year 2022 adjusted EBITDA is expected to be a loss of approximately $2 million to $4 million, and the full year 2022 adjusted loss per share of approximately $1.07 to $1.12.
Positive Outlook
- Revenue is projected to be approximately $315 million to $330 million.
- Revenue reflects growth of approximately 15% to 20% over full year 2021.
Challenges Ahead
- Continued uncertainty relating to the dynamic environment with the COVID-19 pandemic could materially impact this projection.
- Adjusted EBITDA is expected to be a loss of approximately $2 million to $4 million.
- Adjusted loss per share of approximately $1.07 to $1.12.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...